CDTTW · CDT Equity Inc. · Insider Trading

On July 30, 2026, Corvus Capital Limited ("Corvus") entered into that certain securities purchase agreement (the "Agreement") with CDT Equity Inc. (the "Issuer") and certain other investors of Sarborg Limited, a Cayman Islands Company ("Sarborg"), named therein, pursuant to which, on July 30, 2026, Corvus sold to the Issuer an aggregate of 120 shares of Sarborg (such shares the "Sarborg Shares") and the Issuer issued to Corvus as consideration for the Sarborg Shares pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 5,436,830 shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock"), at an exercise price of $0.0001 per share.

The Pre-Funded Warrants include a "cashless" exercise provision, wherein the holder of the Pre-Funded Warrant is entitled to receive a number of shares of Common Stock generally equal to the quotient obtained by dividing the market price minus the exercise price divided by the market price (as further described in the Pre-Funded Warrant). The Pre-Funded Warrants became exercisable on August 28, 2026, following the receipt of stockholder approval for the issuance of the underlying Common Stock, and, on such date, Corvus exercised all of its Pre-Funded Warrants via cashless exercise and received 5,436,540 shares of Common Stock.

These shares of Common Stock and Pre-Funded Warrants are owned of record by Corvus.

The Pre-Funded Warrants have been exercised in full.

Corvus is the owner of 99.0% of the equity interests of Manoira Corporation ("Manoira") and, therefore, may also be deemed to beneficially own the shares of Common Stock held of record by Manoira. Dr. Andrew Regan is the sole director of Manoira and the Chief Executive Officer and sole shareholder of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock and Pre-Funded Warrants held of record by Manoira and Corvus. Each of Corvus and Dr. Regan disclaims any such beneficial ownership, except to the extent of its or his pecuniary interest therein.

On July 30, 2026, Corvus Capital Limited ("Corvus") entered into that certain securities purchase agreement (the "Agreement") with CDT Equity Inc. (the "Issuer") and certain other investors of Sarborg Limited, a Cayman Islands Company ("Sarborg"), named therein, pursuant to which, on July 30, 2026, Corvus sold to the Issuer an aggregate of 120 shares of Sarborg (such shares the "Sarborg Shares") and the Issuer issued to Corvus as consideration for the Sarborg Shares pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 5,436,830 shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock"), at an exercise price of $0.0001 per share.

The Pre-Funded Warrants include a "cashless" exercise provision, wherein the holder of the Pre-Funded Warrant is entitled to receive a number of shares of Common Stock generally equal to the quotient obtained by dividing the market price minus the exercise price divided by the market price (as further described in the Pre-Funded Warrant). The Pre-Funded Warrants became exercisable on August 28, 2026, following the receipt of stockholder approval for the issuance of the underlying Common Stock, and, on such date, Corvus exercised all of its Pre-Funded Warrants via cashless exercise and received 5,436,540 shares of Common Stock.

Corvus exercised the Pre-Funded Warrants on a cashless basis, which resulted in the Issuer withholding 290 shares of Common Stock issuable upon the exercise of the Pre-Funded Warrants to pay the exercise price.

These shares of Common Stock and Pre-Funded Warrants are owned of record by Corvus.

Corvus is the owner of 99.0% of the equity interests of Manoira Corporation ("Manoira") and, therefore, may also be deemed to beneficially own the shares of Common Stock held of record by Manoira. Dr. Andrew Regan is the sole director of Manoira and the Chief Executive Officer and sole shareholder of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock and Pre-Funded Warrants held of record by Manoira and Corvus. Each of Corvus and Dr. Regan disclaims any such beneficial ownership, except to the extent of its or his pecuniary interest therein.

On July 30, 2026, Corvus Capital Limited ("Corvus") entered into that certain securities purchase agreement (the "Agreement") with CDT Equity Inc. (the "Issuer") and certain other investors of Sarborg Limited, a Cayman Islands Company ("Sarborg"), named therein, pursuant to which, on July 30, 2026, Corvus sold to the Issuer an aggregate of 120 shares of Sarborg (such shares the "Sarborg Shares") and the Issuer issued to Corvus as consideration for the Sarborg Shares pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 5,436,830 shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock"), at an exercise price of $0.0001 per share.

The Pre-Funded Warrants include a "cashless" exercise provision, wherein the holder of the Pre-Funded Warrant is entitled to receive a number of shares of Common Stock generally equal to the quotient obtained by dividing the market price minus the exercise price divided by the market price (as further described in the Pre-Funded Warrant). The Pre-Funded Warrants became exercisable on August 28, 2026, following the receipt of stockholder approval for the issuance of the underlying Common Stock, and, on such date, Corvus exercised all of its Pre-Funded Warrants via cashless exercise and received 5,436,540 shares of Common Stock.

These shares of Common Stock and Pre-Funded Warrants are owned of record by Corvus.

Corvus is the owner of 99.0% of the equity interests of Manoira Corporation ("Manoira") and, therefore, may also be deemed to beneficially own the shares of Common Stock held of record by Manoira. Dr. Andrew Regan is the sole director of Manoira and the Chief Executive Officer and sole shareholder of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock and Pre-Funded Warrants held of record by Manoira and Corvus. Each of Corvus and Dr. Regan disclaims any such beneficial ownership, except to the extent of its or his pecuniary interest therein.

On July 30, 2026, Corvus Capital Limited ("Corvus") entered into that certain securities purchase agreement (the "Agreement") with CDT Equity Inc. (the "Issuer") and certain other investors of Sarborg Limited, a Cayman Islands Company ("Sarborg"), named therein, pursuant to which, on July 30, 2026, Corvus sold to the Issuer an aggregate of 120 shares of Sarborg (such shares the "Sarborg Shares") and the Issuer issued to Corvus as consideration for the Sarborg Shares pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 5,436,830 shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock"), at an exercise price of $0.0001 per share.

The Pre-Funded Warrants include a "cashless" exercise provision, wherein the holder of the Pre-Funded Warrant is entitled to receive a number of shares of Common Stock generally equal to the quotient obtained by dividing the market price minus the exercise price divided by the market price (as further described in the Pre-Funded Warrant). The Pre-Funded Warrants became exercisable on August 28, 2026, following the receipt of stockholder approval for the issuance of the underlying Common Stock, and, on such date, Corvus exercised all of its Pre-Funded Warrants via cashless exercise and received 5,436,540 shares of Common Stock.

These shares of Common Stock and Pre-Funded Warrants are owned of record by Corvus.

The Pre-Funded Warrants have been exercised in full.

Corvus is the owner of 99.0% of the equity interests of Manoira Corporation ("Manoira") and, therefore, may also be deemed to beneficially own the shares of Common Stock held of record by Manoira. Dr. Andrew Regan is the sole director of Manoira and the Chief Executive Officer and sole shareholder of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock and Pre-Funded Warrants held of record by Manoira and Corvus. Each of Corvus and Dr. Regan disclaims any such beneficial ownership, except to the extent of its or his pecuniary interest therein.

Number of shares of common stock, par value $0.0001 per share ("Common Stock"), of CDT Equity Inc. (the "Issuer") reported gives effect to the 1-for-25 reverse split of the Common Stock effected by the Company as of the opening of market on March 26, 2026.

On June 18, 2026, Prospect Capital Securities Limited, a New Zealand company ("Prospect Capital") sold 5,000 shares of Common Stock in the open market at a sales price per share of $0.7052 and 1,464,711 shares of Common Stock in the open market at a sales price per share of $1.44.

Mark Taylor is the sole director and sole shareholder of each of Prospect Capital and Prospect Finance Limited, a New Zealand company ("Prospect Finance"). By virtue of these relationships, Mr. Taylor may be deemed to beneficially own the securities held of record by each of Prospect Capital and Prospect Finance. Mr. Taylor disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

Number of shares of common stock, par value $0.0001 per share ("Common Stock"), of CDT Equity Inc. (the "Issuer") reported gives effect to the 1-for-25 reverse split of the Common Stock effected by the Company as of the opening of market on March 26, 2026.

On June 18, 2026, Prospect Capital Securities Limited, a New Zealand company ("Prospect Capital") sold 5,000 shares of Common Stock in the open market at a sales price per share of $0.7052 and 1,464,711 shares of Common Stock in the open market at a sales price per share of $1.44.

Mark Taylor is the sole director and sole shareholder of each of Prospect Capital and Prospect Finance Limited, a New Zealand company ("Prospect Finance"). By virtue of these relationships, Mr. Taylor may be deemed to beneficially own the securities held of record by each of Prospect Capital and Prospect Finance. Mr. Taylor disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

Number of shares of common stock, par value $0.0001 per share ("Common Stock"), of CDT Equity Inc. (the "Issuer") reported gives effect to the 1-for-25 reverse split of the Common Stock effected by the Company as of the opening of market on March 26, 2026.

On June 18, 2026, Prospect Finance sold 5,000 shares of Common Stock in the open market at a sales price per share of $0.751 and 593,289 shares of Common Stock in the open market at prices ranging from $1.25 to $1.67 per share, inclusive.

The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of such shares of Common Stock sold at each separate price within such range.

Mark Taylor is the sole director and sole shareholder of each of Prospect Capital and Prospect Finance Limited, a New Zealand company ("Prospect Finance"). By virtue of these relationships, Mr. Taylor may be deemed to beneficially own the securities held of record by each of Prospect Capital and Prospect Finance. Mr. Taylor disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

Number of shares of common stock, par value $0.0001 per share ("Common Stock"), of CDT Equity Inc. (the "Issuer") reported gives effect to the 1-for-25 reverse split of the Common Stock effected by the Company as of the opening of market on March 26, 2026.

On June 18, 2026, Prospect Finance sold 5,000 shares of Common Stock in the open market at a sales price per share of $0.751 and 593,289 shares of Common Stock in the open market at prices ranging from $1.25 to $1.67 per share, inclusive.

Mark Taylor is the sole director and sole shareholder of each of Prospect Capital and Prospect Finance Limited, a New Zealand company ("Prospect Finance"). By virtue of these relationships, Mr. Taylor may be deemed to beneficially own the securities held of record by each of Prospect Capital and Prospect Finance. Mr. Taylor disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

On May 13, 2026, Corvus purchased a total of 100,000 shares of Common Stock in the open market at a price per share of $1.90 for total cash consideration of $190,000.

These shares of Common Stock are owned of record by Corvus.

Corvus is the owner of 99.0% of the equity interests of Manoira and, therefore, may also be deemed to beneficially own the shares of Common Stock held of record by Manoira. Dr. Regan is the sole director of Manoira and the Chief Executive Officer and sole shareholder of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by Manoira and Corvus. Each of Corvus and Dr. Regan disclaims any such beneficial ownership, except to the extent of its or his pecuniary interest therein.

On March 26, 2026, CDT Equity Inc. (the "Company") effected a 1-for-25 reverse stock split (the "Reverse Stock Split") of the Company's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Corvus ceased to be a 10% holder as of February 19, 2026.

On March 24, 2026, Corvus Capital Limited ("Corvus") exercised all its pre-funded warrants (the "Pre-Funded Warrants") via cashless exercise for 147,401 shares of Common Stock.

The Pre-Funded Warrants have been exercised in full.

These shares of Common Stock are owned of record by Corvus.

Corvus is the owner of 99.0% of the equity interests of Manoira and, therefore, may also be deemed to beneficially own the shares of Common Stock held of record by Manoira. Dr. Regan is the sole director of Manoira and the Chief Executive Officer and sole shareholder of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by Manoira and Corvus. Each of Corvus and Dr. Regan disclaims any such beneficial ownership, except to the extent of its or his pecuniary interest therein.

On March 26, 2026, CDT Equity Inc. (the "Company") effected a 1-for-25 reverse stock split (the "Reverse Stock Split") of the Company's outstanding shares of common stock, par value $0.0001 per share (the "Common Stock"). The number of shares of Common Stock and prices reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Corvus ceased to be a 10% holder as of February 19, 2026.

On March 24, 2026, Corvus Capital Limited ("Corvus") exercised all its pre-funded warrants (the "Pre-Funded Warrants") via cashless exercise for 147,401 shares of Common Stock.

These shares of Common Stock are owned of record by Corvus.

Corvus is the owner of 99.0% of the equity interests of Manoira and, therefore, may also be deemed to beneficially own the shares of Common Stock held of record by Manoira. Dr. Regan is the sole director of Manoira and the Chief Executive Officer and sole shareholder of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by Manoira and Corvus. Each of Corvus and Dr. Regan disclaims any such beneficial ownership, except to the extent of its or his pecuniary interest therein.

On March 17, 2026, following the certification of the results of the Issuer's special meeting of stockholders wherein the stockholders approved the issuance of Common Stock upon the exercise of the Pre-Funded Warrants, the Pre-Funded Warrants became exercisable and Prospect Capital and Prospect Finance each exercised all of their Pre-Funded Warrants pursuant to the "cashless" exercise provision thereof and received 36,544,028 and 14,876,330 shares of Common Stock, respectively. The Pre-Funded Warrants have no expiration date and are exercisable until exercised in full.

Mark Taylor is the sole director and sole shareholder of each of Prospect Capital Securities Limited, a New Zealand company ("Prospect Capital"), and Prospect Finance. By virtue of these relationships, Mr. Taylor may be deemed to beneficially own the securities held of record by each of Prospect Capital and Prospect Finance. Mr. Taylor disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

On March 17, 2026, following the certification of the results of the Issuer's special meeting of stockholders wherein the stockholders approved the issuance of Common Stock upon the exercise of the Pre-Funded Warrants, the Pre-Funded Warrants became exercisable and Prospect Capital and Prospect Finance each exercised all of their Pre-Funded Warrants pursuant to the "cashless" exercise provision thereof and received 36,544,028 and 14,876,330 shares of Common Stock, respectively. The Pre-Funded Warrants have no expiration date and are exercisable until exercised in full.

On February 19, 2026, Prospect Finance Limited, a New Zealand company ("Prospect Finance"), transferred (i) 46,902 shares of common stock, par value $0.0001 per share (the "Common Stock"), of CDT Equity Inc. (the "Issuer"), and (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase 9,968,931 shares of Common Stock, to a third party, each for no consideration.

Mark Taylor is the sole director and sole shareholder of each of Prospect Capital Securities Limited, a New Zealand company ("Prospect Capital"), and Prospect Finance. By virtue of these relationships, Mr. Taylor may be deemed to beneficially own the securities held of record by each of Prospect Capital and Prospect Finance. Mr. Taylor disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

On February 19, 2026, CDT Equity Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with the reporting person and other stockholders (the "Investors") of Sarborg Limited, a Cayman Islands Company ("Sarborg"), pursuant to which the reporting person agreed to sell to the Company, and the Company agreed to acquire from the reporting person, 18 shares of Sarborg having an aggregate value of approximately $2,029,411 in exchange for (i) 10,553 shares of the Company's Common Stock, and (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 1,940,804 shares of the Company's Common Stock, reflecting a purchase price of $1.04 per share.

On February 19, 2026, Prospect Finance Limited, a New Zealand company ("Prospect Finance"), transferred (i) 46,902 shares of common stock, par value $0.0001 per share (the "Common Stock"), of CDT Equity Inc. (the "Issuer"), and (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase 9,968,931 shares of Common Stock, to a third party, each for no consideration.

Mark Taylor is the sole director and sole shareholder of each of Prospect Capital Securities Limited, a New Zealand company ("Prospect Capital"), and Prospect Finance. By virtue of these relationships, Mr. Taylor may be deemed to beneficially own the securities held of record by each of Prospect Capital and Prospect Finance. Mr. Taylor disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

On February 19, 2026, Prospect Finance Limited, a New Zealand company ("Prospect Finance"), transferred (i) 46,902 shares of common stock, par value $0.0001 per share (the "Common Stock"), of CDT Equity Inc. (the "Issuer"), and (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase 9,968,931 shares of Common Stock, to a third party, each for no consideration.

On March 17, 2026, following the certification of the results of the Issuer's special meeting of stockholders wherein the stockholders approved the issuance of Common Stock upon the exercise of the Pre-Funded Warrants, the Pre-Funded Warrants became exercisable and Prospect Capital and Prospect Finance each exercised all of their Pre-Funded Warrants pursuant to the "cashless" exercise provision thereof and received 36,544,028 and 14,876,330 shares of Common Stock, respectively. The Pre-Funded Warrants have no expiration date and are exercisable until exercised in full.

Mark Taylor is the sole director and sole shareholder of each of Prospect Capital Securities Limited, a New Zealand company ("Prospect Capital"), and Prospect Finance. By virtue of these relationships, Mr. Taylor may be deemed to beneficially own the securities held of record by each of Prospect Capital and Prospect Finance. Mr. Taylor disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

On February 19, 2026, CDT Equity Inc. (the "Company") entered into a Securities Purchase Agreement (the "Purchase Agreement") with the reporting person and other stockholders (the "Investors") of Sarborg Limited, a Cayman Islands Company ("Sarborg"), pursuant to which the reporting person agreed to sell to the Company, and the Company agreed to acquire from the reporting person, 18 shares of Sarborg having an aggregate value of approximately $2,029,411 in exchange for (i) 10,553 shares of the Company's Common Stock, and (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 1,940,804 shares of the Company's Common Stock, reflecting a purchase price of $1.04 per share.

The Pre-Funded Warrants may not be exercised until the Company obtains requisite stockholder approval in accordance with Nasdaq Listing Rule 5635.

The Pre-Funded Warrants will remain exercisable until all Pre-Funded Warrants are exercised in full.

On December 8, 2025, CDT Equity Inc. (the "Company") and Corvus Capital Limited ("Corvus") entered into a Sale and Purchase Agreement, pursuant to which the Company issued to Corvus 224,800 shares of common stock, par value $0.0001 per share of the Company, and pre-funded warrants to purchase up to 3,685,815 shares of Common Stock (the "Pre-Funded Warrants"), pursuant to the acquisition of Conduit Pharmaceuticals Limited and its liabilities.

Based on the closing price per share of Common Stock on December 7, 2025.

These shares of Common Stock are owned of record by Corvus.

Corvus is the owner of 99.0% of the equity interests of Manoira and Algo is a wholly owned subsidiary of Corvus, and, therefore, may also be deemed to beneficially own the shares of Common Stock held of record by Manoira and Algo. Dr. Regan is the sole director of Manoira and the Chief Executive Officer and sole shareholder of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by Manoira, Algo and Corvus. Each of Corvus and Dr. Regan disclaims any such beneficial ownership, including with respect to the Pre-Funded Warrant Shares, except to the extent of its or his pecuniary interest therein.

On December 8, 2025, CDT Equity Inc. (the "Company") and Corvus Capital Limited ("Corvus") entered into a Sale and Purchase Agreement, pursuant to which the Company issued to Corvus 224,800 shares of common stock, par value $0.0001 per share of the Company, and pre-funded warrants to purchase up to 3,685,815 shares of Common Stock (the "Pre-Funded Warrants"), pursuant to the acquisition of Conduit Pharmaceuticals Limited and its liabilities.

Until exercised in full.

These shares of Common Stock are owned of record by Corvus.

Corvus is the owner of 99.0% of the equity interests of Manoira and Algo is a wholly owned subsidiary of Corvus, and, therefore, may also be deemed to beneficially own the shares of Common Stock held of record by Manoira and Algo. Dr. Regan is the sole director of Manoira and the Chief Executive Officer and sole shareholder of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by Manoira, Algo and Corvus. Each of Corvus and Dr. Regan disclaims any such beneficial ownership, including with respect to the Pre-Funded Warrant Shares, except to the extent of its or his pecuniary interest therein.

On September 19, 2025, CDT Equity Inc. (formerly known as Conduit Pharmaceuticals Inc. (the "Issuer")) granted Dr. Andrew Regan ("Dr. Regan") 1,120,000 shares of common stock, par value $0.0001 ("Common Stock"), of the Issuer pursuant to the Issuer's Amended and Restated 2023 Stock Incentive Plan as compensation for his services as a director and an officer of the Issuer.

Based on the closing price per share of Common Stock on September 18, 2025.

Represents shares of restricted stock granted on September 19, 2025 under the Issuer's Amended and Restated 2023 Stock Incentive Plan having a value equal to approximately $329,424 based on the closing price per share of the Issuer's common stock on September 18, 2025. The shares of restricted stock vest immediately upon grant.

Represents restricted stock units ("RSUs") received on August 12, 2025, in exchange for past services, having a value equal to approximately $60,900 based on the closing price per share of the Issuer's common stock on August 12, 2025. The RSUs vest immediately upon grant.

Represents restricted stock units ("RSUs") received on August 12, 2025, in exchange for past services, having a value equal to approximately $60,900 based on the closing price per share of the Issuer's common stock on August 12, 2025. The RSUs vest immediately upon grant.

Represents restricted stock units ("RSUs") received on August 12, 2025, in exchange for past services, having a value equal to approximately $60,900 based on the closing price per share of the Issuer's common stock on August 12, 2025. The RSUs vest immediately upon grant.

Represents options to purchase common stock, granted under the Issuer's 2023 Stock Incentive Plan, which were granted at the conclusion of the Issuer's 2025 annual meeting of stockholders.

The options vest immediately upon grant.

Represents options to purchase common stock, granted under the Issuer's 2023 Stock Incentive Plan, which were granted at the conclusion of the Issuer's 2025 annual meeting of stockholders.

The options vest immediately upon grant.

Represents options to purchase common stock, granted under the Issuer's 2023 Stock Incentive Plan, which were granted at the conclusion of the Issuer's 2025 annual meeting of stockholders.

The options vest immediately upon grant.

Based on the closing price per share of the Issuer's common stock, par value $0.0001 ("Common Stock"), on June 3, 2025.

These shares of Common Stock are owned of record by Manoira Corporation ("Manoira"). On June 3, 2025, the Issuer issued 154,799 shares of Common Stock to Manoira pursuant to that certain joint development agreement (the "Joint Development Agreement") by and between the Issuer and Manoira, representing an up-front consideration of $500,000.

Represents shares issued pursuant to the 2023 Stock Incentive Plan, in lieu of $26,125 accrued in cash retainers under the Issuer's Non-Employee Director Compensation Program.

Represents shares issued pursuant to the 2023 Stock Incentive Plan, in lieu of $41,500 accrued in cash retainers under the Issuer's Non-Employee Director Compensation Program.

Represents shares issued pursuant to the 2023 Stock Incentive Plan, in lieu of $28,500 accrued in cash retainers under the Issuer's Non-Employee Director Compensation Program.

Represents shares issued pursuant to the 2023 Stock Incentive Plan, in lieu of $42,375 accrued in cash retainers under the Issuer's Non-Employee Director Compensation Program.

Represents options to purchase common stock, granted under the Issuer's 2023 Stock Incentive Plan, which were granted at the conclusion of the Issuer's 2024 annual meeting of stockholders.

The options will vest on the earlier of (x) the first anniversary of the date of grant, or (y) the date immediately prior to the next annual meeting of the Issuer's stockholders following the date of grant.

Represents options to purchase common stock, granted under the Issuer's 2023 Stock Incentive Plan, which were granted at the conclusion of the Issuer's 2024 annual meeting of stockholders.

The options will vest on the earlier of (x) the first anniversary of the date of grant, or (y) the date immediately prior to the next annual meeting of the Issuer's stockholders following the date of grant.

Represents options to purchase common stock, granted under the Issuer's 2023 Stock Incentive Plan, which were granted at the conclusion of the Issuer's 2024 annual meeting of stockholders.

The options will vest in equal annual installments on the first three anniversaries of the grant date.

Represents options to purchase common stock, granted under the Issuer's 2023 Stock Incentive Plan, which were granted at the conclusion of the Issuer's 2024 annual meeting of stockholders.

The options will vest on the earlier of (x) the first anniversary of the date of grant, or (y) the date immediately prior to the next annual meeting of the Issuer's stockholders following the date of grant.

Represents Options to purchase common stock, granted under the Issuer's 2023 Stock Incentive Plan.

The Options vest as follows: (i) 50% on the grant date and (ii) 50% in equal annual installments on the first three anniversaries of the grant date.

The shares are fully vested and were granted under the Issuer's 2023 Stock Incentive Plan.

Represents shares issued in lieu of $40,250 accrued in cash retainers under the Issuer's Non-Employee Director Compensation Program.

Represents shares issued in lieu of $24,500 accrued in cash retainers under the Issuer's Non-Employee Director Compensation Program.

Represents shares issued in lieu of $27,500 accrued in cash retainers under the Issuer's Non-Employee Director Compensation Program.

Represents Options to purchase common stock, granted under the Issuer's 2023 Stock Incentive Plan.

The Options vest as follows: (i) 50% on the grant date and (ii) 50% in equal annual installments on the first three anniversaries of the grant date.

Nirland Limited, a company registered in Guernsey with company number 58804 of The Old Stables Rue a L'Or, St Peter Port, GUERNSEY GY1 1QG ("Nirland Limited") is wholly owned by Stockton Limited, a company registered in Guernsey ("Stockton Limited"), which is wholly owned by The Rowland Master Trust, a Guernsey trust ("The Rowland Master Trust"). Dovet Limited, a company registered in Guernsey ("Dovet Limited"), is the sole trustee of The Rowland Master Trust. By virtue of these relationships, each of Stockton Limited, The Rowland Master Trust and Dovet Limited may be deemed to share beneficial ownership of the securities held of record by Nirland Limited.

Nirland Limited, a company registered in Guernsey with company number 58804 of The Old Stables Rue a L'Or, St Peter Port, GUERNSEY GY1 1QG ("Nirland Limited") is wholly owned by Stockton Limited, a company registered in Guernsey ("Stockton Limited"), which is wholly owned by The Rowland Master Trust, a Guernsey trust ("The Rowland Master Trust"). Dovet Limited, a company registered in Guernsey ("Dovet Limited"), is the sole trustee of The Rowland Master Trust. By virtue of these relationships, each of Stockton Limited, The Rowland Master Trust and Dovet Limited may be deemed to share beneficial ownership of the securities held of record by Nirland Limited.

Nirland Limited, a company registered in Guernsey with company number 58804 of The Old Stables Rue a L'Or, St Peter Port, GUERNSEY GY1 1QG ("Nirland Limited") is wholly owned by Stockton Limited, a company registered in Guernsey ("Stockton Limited"), which is wholly owned by The Rowland Master Trust, a Guernsey trust ("The Rowland Master Trust"). Dovet Limited, a company registered in Guernsey ("Dovet Limited"), is the sole trustee of The Rowland Master Trust. By virtue of these relationships, each of Stockton Limited, The Rowland Master Trust and Dovet Limited may be deemed to share beneficial ownership of the securities held of record by Nirland Limited.

Nirland Limited, a company registered in Guernsey with company number 58804 of The Old Stables Rue a L'Or, St Peter Port, GUERNSEY GY1 1QG ("Nirland Limited") is wholly owned by Stockton Limited, a company registered in Guernsey ("Stockton Limited"), which is wholly owned by The Rowland Master Trust, a Guernsey trust ("The Rowland Master Trust"). Dovet Limited, a company registered in Guernsey ("Dovet Limited"), is the sole trustee of The Rowland Master Trust. By virtue of these relationships, each of Stockton Limited, The Rowland Master Trust and Dovet Limited may be deemed to share beneficial ownership of the securities held of record by Nirland Limited.

Nirland Limited, a company registered in Guernsey with company number 58804 of The Old Stables Rue a L'Or, St Peter Port, GUERNSEY GY1 1QG ("Nirland Limited") is wholly owned by Stockton Limited, a company registered in Guernsey ("Stockton Limited"), which is wholly owned by The Rowland Master Trust, a Guernsey trust ("The Rowland Master Trust"). Dovet Limited, a company registered in Guernsey ("Dovet Limited"), is the sole trustee of The Rowland Master Trust. By virtue of these relationships, each of Stockton Limited, The Rowland Master Trust and Dovet Limited may be deemed to share beneficial ownership of the securities held of record by Nirland Limited.

Nirland Limited, a company registered in Guernsey with company number 58804 of The Old Stables Rue a L'Or, St Peter Port, GUERNSEY GY1 1QG ("Nirland Limited") is wholly owned by Stockton Limited, a company registered in Guernsey ("Stockton Limited"), which is wholly owned by The Rowland Master Trust, a Guernsey trust ("The Rowland Master Trust"). Dovet Limited, a company registered in Guernsey ("Dovet Limited"), is the sole trustee of The Rowland Master Trust. By virtue of these relationships, each of Stockton Limited, The Rowland Master Trust and Dovet Limited may be deemed to share beneficial ownership of the securities held of record by Nirland Limited.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.255-0.265, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold at each separate price within the range. Following the sales of shares of Common Stock as reported in this Form 4, Algo no longer holds 10% of the outstanding shares of Common Stock of the Issuer.

Dr. Regan is the Chief Executive Officer and sole shareholder of Corvus. Algo is a wholly owned subsidiary of Corvus. By virtue of these relationships, Dr. Regan may be deemed to beneficially own the shares of Common Stock held of record by each of Corvus and Algo. Dr. Regan disclaims any such beneficial ownership except to the extent of his pecuniary interest therein.

The securities are owned solely by Algo. On March 26, 2024, Algo pledged certain shares of Common Stock to a financial institution as collateral for a loan, pursuant to that certain Control and Restricted Loan Agreement, dated March 26, 2024, by and between Algo and such financial institution (the "Loan Agreement"). The loan proceeds were used to pay a portion of certain amounts due to a third party investor in the Issuer as an inducement to such investment to the Issuer in September 2023, pursuant to an agreement entered into by and among Algo, Corvus and such third party. These shares of Common Stock were sold by such financial institution pursuant to the terms and conditions of the Loan Agreement.